Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas

Authors

  • Joséphine Franceschi Department of Dermatology, Reims University Hospital, rue du Général Koenig, FR-51100 Reims, France
  • Marine Ehret
  • Laetitia Visseaux
  • Anne Durlach
  • Coralie Barbe
  • Éric Durot
  • Florent Grange

DOI:

https://doi.org/10.2340/actadv.v102.1087

Keywords:

aggressive cutaneous T-cell lymphoma, mycosis fungoides, Sézary syndrome, prognosis, survival

Abstract

Aggressive primary cutaneous T-cell lymphomas include advanced-stage mycosis fungoides (stage ≥ IIB mycosis fungoides), Sézary syndrome, gamma/delta cutaneous lymphoma, nasal type lymphoma, aggressive epidermotropic CD8+ T-cell lymphoma and some cutaneous lymphomas not otherwise specified. To evaluate their long-term prognosis, we conducted a retrospective cohort study of 85 patients diagnosed between 2005 and 2020 with advanced-stage mycosis fungoides (n = 48), Sézary syndrome (n = 28) or aggressive non-mycosis fungoides/Sézary syndrome subtypes (n = 9). The median survival times in these 3 groups were 118.7, 45.7 and 11.2 months, respectively, and the 5-year survival rates were 55.3%, 27.8% and 33.3%, respectively. Multivariate analyses in patients with mycosis fungoides/Sézary syndrome identified age ≥ 70 years, Eastern Cooperative Oncology Group Performance Status ≥  2, and the high-risk group according to the Cutaneous Lymphoma International Consortium prognostic model, as adverse prognostic factors. Seven patients in this mycosis fungoides/ Sézary syndrome group were in complete long-term remission after treatment with bexarotene, including 4 patients living without any treatment for 16–101 months.

Downloads

Download data is not yet available.

References

Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.

https://doi.org/10.1182/blood-2004-09-3502

Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92: 1240-1251.

https://doi.org/10.1093/jnci/92.15.1240

Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064-5073.

https://doi.org/10.1182/blood-2008-10-184168

Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.

https://doi.org/10.1182/blood-2007-03-055749

Mourad A, Gniadecki R. Overall survival in mycosis fungoides: a systematic review and meta-analysis. J Invest Dermatol 2020; 140: 495-497.

https://doi.org/10.1016/j.jid.2019.07.712

Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous Lymphoma International Consortium Study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol Off J Am Soc Clin Oncol 2015; 33: 3766-3773.

https://doi.org/10.1200/JCO.2015.61.7142

Scarisbrick JJ, Kim YH, Whittaker SJ, Wood GS, Vermeer MH, Prince HM, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br J Dermatol 2014; 170: 1226-1236.

https://doi.org/10.1111/bjd.12909

Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer Oxf Engl 1990 2013; 49: 2859-2868.

https://doi.org/10.1016/j.ejca.2013.04.018

Laban É, Beylot-Barry M, Ortonne N, Battistella M, Carlotti A, de Muret A, et al. Lymphoproliférations cutanées: proposition d'algorithmes diagnostiques à partir de l'expérience sur 2 ans des réseaux INCa (LYMPHOPATH et GFELC) sur 2760 lymphoproliférations cutanées. Ann Pathol 2015; 35: 131-147.

https://doi.org/10.1016/j.annpat.2015.02.001

Grange F, Hedelin G, Joly P, Beylot-Barry M, D'Incan M, Delaunay M, et al. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas. Blood 1999; 93: 3637-3642.

Bouaziz J-D, Bastuji-Garin S, Poszepczynska-Guigné E, Wechsler J, Bagot M. Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single-centre study of 203 patients. Br J Dermatol 2006; 154: 1206-1207.

https://doi.org/10.1111/j.1365-2133.2006.07264.x

Beylot-Barry M, Vergier B, Masquelier B, Bagot M, Joly P, Souteyrand P, et al. The spectrum of cutaneous lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol 1999; 23: 1208-1216.

https://doi.org/10.1097/00000478-199910000-00005

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375-2390.

https://doi.org/10.1182/blood-2016-01-643569

Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484.

https://doi.org/10.1182/blood-2006-10-054601

Salhany KE, Cousar JB, Greer JP, Casey TT, Fields JP, Collins RD. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol 1988; 132: 265-277.

Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999; 40: 418-425.

https://doi.org/10.1016/S0190-9622(99)70491-3

Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res 2012; 18: 5051-5060.

https://doi.org/10.1158/1078-0432.CCR-12-0604

Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139: 857-866.

https://doi.org/10.1001/archderm.139.7.857

Nikolaou V, Papadavid E, Patsatsi A, Siakantaris M, Economidi A, Marinos L, et al. Prognostic indicators for mycosis fungoides in a Greek population. Br J Dermatol 2017; 176: 1321-1330.

https://doi.org/10.1111/bjd.15000

Danish HH, Liu S, Jhaveri J, Flowers CR, Lechowicz MJ, Esiashvili N, et al. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome. Leuk Lymphoma 2016; 57: 2813-2819.

https://doi.org/10.3109/10428194.2016.1173210

Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-2471.

https://doi.org/10.1200/JCO.2001.19.9.2456

Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47: 672-684.

https://doi.org/10.1067/mjd.2002.124607

Downloads

Published

2022-03-22

How to Cite

Franceschi, J., Ehret, M., Visseaux, L., Durlach, A., Barbe, C., Durot, Éric, & Grange, F. (2022). Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas. Acta Dermato-Venereologica, 102, adv00676. https://doi.org/10.2340/actadv.v102.1087

Issue

Section

Articles

Categories